Trial Profile

Impact of abemaciclib on patients' roles and responsibilities: a multi-centre observational quality of life study with nested qualitative interview study

Status: Completed

Phase of Trial: Phase III/IV

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms IMPACTOR

Most Recent Events

26 Apr 2025 Results assessing whether incidence and management of diarrhoea associated with abemaciclib and endocrine therapy published in the Supportive Care in Cancer
03 Jul 2023 Status changed from active, no longer recruiting to completed.
02 Jan 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com